Education to Improve Pneumococcal Vaccine Uptake Among Older Adults (PROPEL)

January 22, 2024 updated by: University of Ottawa

Assessing Barriers to Pneumococcal Vaccination to Increase Vaccine Uptake Among Older Adults: a Web-based Educational Intervention

The goal of this trial is to compare the effect of a web-based educational video about pneumococcal vaccines and a reminder email to get vaccinated (intervention) with a reminder email alone (comparator) in adults aged 65 or older living in any Canadian province who reported not having received a pneumococcal vaccine.

The main questions this trial aims to answer are:

  1. does the educational intervention improve pneumococcal vaccine uptake,
  2. does the educational intervention improve willingness to be vaccinated,
  3. does the educational intervention improve knowledge of pneumococcal vaccination,
  4. and does the educational intervention improve attitudes towards pneumococcal vaccines/vaccination?

Eligible participants who provide electronic consent will:

  1. fill out a web-based baseline survey,
  2. receive access to the educational video (if assigned to the intervention group),
  3. receive an email reminder to be vaccinated (both groups),
  4. and fill in a web-based follow-up survey.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This research project is a web-based randomized controlled trial (RCT), targeting adults aged 65 years and older across all Canadian provinces. The primary objectives of this study are twofold. Firstly, it aims to assess the participants' knowledge, barriers, facilitators, and willingness to receive the pneumococcal vaccine at baseline. Secondly, it aims to evaluate the impact of a video-led educational intervention on pneumococcal vaccine literacy, willingness to be vaccinated, and the actual uptake of the vaccine. To this end, participants will be recruited through various online channels. Only individuals who have not received the pneumococcal vaccine will be considered eligible for inclusion. For the second objective, participants will be randomly assigned to either the intervention group (short video on pneumococcal vaccination) or the control group (reminder to receive a pneumococcal vaccine). Consenting participants will be required to complete two surveys: one at baseline and another approximately six months post-intervention. These surveys will provide valuable data for analyzing the effectiveness of the educational intervention in improving participants' knowledge, willingness to be vaccinated, and the actual uptake of the pneumococcal vaccine. Findings from this research will contribute to the understanding of factors influencing pneumococcal vaccine decision-making among older adults, ultimately informing strategies to enhance vaccine uptake and public health outcomes in this population.

Study Type

Interventional

Enrollment (Estimated)

786

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion criteria:

  1. adults aged ≥ 65 residing in any Canadian province,
  2. community dwelling (i.e., living outside of nursing homes),
  3. reporting not having received a pneumococcal vaccine, and
  4. being able to understand English and/or French.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Web-based educational video on pneumococcal vaccination and reminder email to be vaccinated
Other: Web-based educational video on pneumococcal vaccination
Participants will receive a link to view a short video on pneumococcal vaccination.
Other: Reminder email to be vaccinated
Participants will receive a reminder email to be vaccinated.
Placebo Comparator: Reminder email to be vaccinated
Other: Reminder email to be vaccinated
Participants will receive a reminder email to be vaccinated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pneumococcal vaccine uptake measured using a web-based follow-up survey four to six months post-randomization
Time Frame: 4-6 months
Participants will be asked at follow-up whether they received a pneumococcal vaccine since the last survey (yes/no/do not know).
4-6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in pneumococcal vaccination willingness, measured using web-based surveys (one at baseline and one four to six months post-randomization)
Time Frame: 4-6 months
Participants will be asked at baseline and follow-up whether they would be willing to receive a pneumococcal vaccine (yes/no/do not know).
4-6 months
Change in pneumococcal vaccine knowledge measured using web-based surveys (one at baseline and one four to six months post-randomization)
Time Frame: 4-6 months
Participants will be asked about their vaccine knowledge at baseline and follow-up (yes/no/do not know).
4-6 months
Change in pneumococcal vaccine attitudes measured using web-based surveys (one at baseline and one four to six months post-randomization)
Time Frame: 4-6 months
Participants will be asked about their vaccine attitudes using Likert-type questions at baseline and follow-up.
4-6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Ottawa

Investigators

  • Principal Investigator: Giorgia Sulis, PhD, School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2024

Primary Completion (Estimated)

March 1, 2025

Study Completion (Estimated)

March 1, 2025

Study Registration Dates

First Submitted

January 22, 2024

First Submitted That Met QC Criteria

January 22, 2024

First Posted (Estimated)

January 31, 2024

Study Record Updates

Last Update Posted (Estimated)

January 31, 2024

Last Update Submitted That Met QC Criteria

January 22, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CIRN Project SH-34

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumococcal Vaccine Uptake

Clinical Trials on Web-based educational video on pneumococcal vaccination

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe